Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer

Inclusion Criteria: * Histologically-confirmed T1b, T2 or T3 gallbladder cancer discovered incidentally at the time of or following routine cholecystectomy for presumed benign disease * Resectable disease at the time of enrollment based on high-quality, preoperative, cross-sectional imaging of the chest, abdomen, and pelvis (C/A/P) * Enrollment and randomization within 12 weeks of initial cholecystectomy * High-quality cross-sectional imaging (computed tomography \[CT\] or magnetic resonance imaging \[MRI\]) performed within 4 weeks prior to enrollment * Able to give informed consent * Able to adhere to study visit schedule and other protocol requirements * Eastern Cooperative Oncology Group (ECOG) performance status of \< 2 * Absolute neutrophil count ≥ 1500/mm³ * Platelet count ≥ 100,000/mm³ Exclusion Criteria: * Patients with histologically-confirmed Tis, T1a, or T4 tumors * Unresectable gallbladder cancer at the time of enrollment based on high-quality, preoperative, cross-sectional imaging of the C/A/P * Unable to sign informed consent * Serum creatinine \> 1.5 x upper limit of normal or estimated creatinine clearance (CrCl) \< 45 ml/min * Serum total bilirubin \> 1.5 x upper limit of normal * Presence of active infection * Pregnant and/or breastfeeding * Known dihydropyrimidine dehydrogenase deficiency